June 10, 2021

Three F.D.A. Advisers Resign Over Agency’s Approval of Alzheimer’s Drug

By Pam Belluck Rebecca Robbins

1,265 words

The drug, Aduhelm, a monthly infusion priced at $56,000 per year, was approved this week despite weak evidence that it helps patients.

Read original article (archived)

Refreshed on June 10, 2021 at 11:49:12 pm

Headlines and popularity

  1. Three F.D.A. Advisers Resign Over Agency’s Approval of Alzheimer’s Drug
  2. 3 F.D.A. Advisers Resign Over Approval of Alzheimer’s Drug
  3. Some F.D.A. Advisers Resign Over Approval of Alzheimer’s Drug

At a glance

298,589 views
3 headlines observed
2 days on front page

#7 viewed

at its peak

#2 shared

at its peak

#7 emailed

at its peak

Headlines

  • Three F.D.A. Advisers Resign Over Agency’s Approval of Alzheimer’s Drug
  • 3 F.D.A. Advisers Resign Over Approval of Alzheimer’s Drug
  • Some F.D.A. Advisers Resign Over Approval of Alzheimer’s Drug

Tags

  • Aduhelm (Drug)
  • Alzheimer's Disease
  • Biogen Inc
  • Clinical Trials
  • Drugs (Pharmaceuticals)
  • Elderly
  • your-feed-science